PriceTargets.com logo

NASDAQ:ASMB - Assembly Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.90
  • Forecasted Upside: 270.89 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.13 As of 08/16/2022 10:54 AM ET
▼ -0.02 (-0.93%)

This chart shows the closing price for ASMB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Assembly Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ASMB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ASMB

Analyst Price Target is $7.90
▲ +270.89% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Assembly Biosciences in the last 3 months. The average price target is $7.90, with a high forecast of $14.00 and a low forecast of $2.50. The average price target represents a 270.89% upside from the last price of $2.13.

This chart shows the closing price for ASMB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Assembly Biosciences. This rating has held steady since April 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/20/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/18/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/16/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/17/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/16/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/15/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/21/2022HC WainwrightLower Price Target$3.50 ➝ $2.50Low
4/1/2022Truist FinancialLower Price TargetBuy$15.00 ➝ $12.00High
3/22/2022MizuhoInitiated CoverageBuy$14.00Medium
9/13/2021HC WainwrightInitiated CoverageNeutral$3.50Medium
9/2/2021William BlairDowngradeOutperform ➝ Market Perform$3.10High
5/11/2021MizuhoReiterated RatingBuy$13.00Low
5/10/2021SVB LeerinkLower Price TargetMarket Perform$8.00 ➝ $7.00Medium
3/29/2021SVB LeerinkReiterated RatingOutperform ➝ Market Perform$9.00 ➝ $8.00N/A
3/23/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$9.00 ➝ $8.00High
3/2/2021Truist FinancialLower Price Target$45.00 ➝ $15.00Low
2/28/2021Robert W. BairdReiterated RatingBuyLow
2/25/2021MizuhoReiterated RatingBuy$13.00Low
12/4/2020MizuhoLower Price TargetBuy$30.00 ➝ $13.00High
11/6/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$30.00 ➝ $10.00High
10/19/2020Truist FinancialInitiated CoverageBuy$55.00High
8/28/2020SVB LeerinkReiterated RatingOutperformLow
7/8/2020SVB LeerinkBoost Price TargetOutperform$36.00 ➝ $38.00Medium
6/25/2020William BlairReiterated RatingBuyLow
5/12/2020William BlairReiterated RatingBuyHigh
5/8/2020MizuhoReiterated RatingBuy$30.00High
4/6/2020MizuhoReiterated RatingBuy$30.00High
11/7/2019William BlairReiterated RatingBuyHigh
10/17/2019Robert W. BairdSet Price TargetBuy$74.00Low
10/15/2019MizuhoInitiated CoverageBuy$20.00High
10/2/2019William BlairReiterated RatingBuyHigh
9/19/2019Chardan CapitalReiterated RatingNeutralHigh
8/7/2019Chardan CapitalReiterated RatingHold$30.00High
7/16/2019William BlairReiterated RatingBuyLow
6/30/2019Chardan CapitalReiterated RatingHoldHigh
5/10/2019William BlairReiterated RatingOutperformHigh
4/15/2019Chardan CapitalReiterated RatingHold$30.00High
11/19/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$45.00Medium
10/28/2018Chardan CapitalReiterated RatingNeutralHigh
10/8/2018B. RileyUpgradeNeutral ➝ Buy$42.00 ➝ $42.00High
8/8/2018Robert W. BairdInitiated CoverageOutperform$74.00Low
5/8/2018B. RileyLower Price TargetNeutral ➝ Neutral$45.00High
4/13/2018Chardan CapitalDowngradeBuy ➝ Neutral$35.00 ➝ $50.00High
3/8/2018Jefferies Financial GroupBoost Price TargetBuy$75.00Medium
1/5/2018B. RileyInitiated CoverageNeutral ➝ Neutral$35.00High
11/8/2017Jefferies Financial GroupInitiated CoverageBuy$50.00N/A
9/17/2017Chardan CapitalReiterated RatingBuyMedium
(Data available from 8/16/2017 forward)

News Sentiment Rating

0.17 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 12 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
1/18/2022
  • 6 very positive mentions
  • 73 positive mentions
  • 12 negative mentions
  • 2 very negative mentions
Mentions as of
2/17/2022
  • 9 very positive mentions
  • 62 positive mentions
  • 11 negative mentions
  • 6 very negative mentions
Mentions as of
3/19/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/18/2022
  • 8 very positive mentions
  • 47 positive mentions
  • 11 negative mentions
  • 4 very negative mentions
Mentions as of
5/18/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/17/2022
  • 3 very positive mentions
  • 12 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
7/17/2022
  • 3 very positive mentions
  • 17 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
8/16/2022

Current Sentiment

  • 3 very positive mentions
  • 17 positive mentions
  • 5 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Assembly Biosciences logo
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $2.13
Low: $2.13
High: $2.15

50 Day Range

MA: $2.11
Low: $1.89
High: $2.34

52 Week Range

Now: $2.13
Low: $1.32
High: $3.94

Volume

910 shs

Average Volume

407,125 shs

Market Capitalization

$103.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7

Frequently Asked Questions

What sell-side analysts currently cover shares of Assembly Biosciences?

The following Wall Street analysts have issued research reports on Assembly Biosciences in the last year: HC Wainwright, Mizuho, StockNews.com, Truist Financial Co., and William Blair.
View the latest analyst ratings for ASMB.

What is the current price target for Assembly Biosciences?

4 Wall Street analysts have set twelve-month price targets for Assembly Biosciences in the last year. Their average twelve-month price target is $7.90, suggesting a possible upside of 270.9%. Mizuho has the highest price target set, predicting ASMB will reach $14.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $2.50 for Assembly Biosciences in the next year.
View the latest price targets for ASMB.

What is the current consensus analyst rating for Assembly Biosciences?

Assembly Biosciences currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ASMB will outperform the market and that investors should add to their positions of Assembly Biosciences.
View the latest ratings for ASMB.

What other companies compete with Assembly Biosciences?

Other companies that are similar to Assembly Biosciences include Endo International, Paratek Pharmaceuticals, Cumberland Pharmaceuticals, Entasis Therapeutics and CytomX Therapeutics. Learn More about companies similar to Assembly Biosciences.

How do I contact Assembly Biosciences' investor relations team?

Assembly Biosciences' physical mailing address is 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company's listed phone number is (833) 509-4583 and its investor relations email address is [email protected] The official website for Assembly Biosciences is www.assemblybio.com. Learn More about contacing Assembly Biosciences investor relations.